Krystal Biotech (KRYS) Stock Forecast, Price & News

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

Is Krystal Biotech a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Krystal Biotech stock.
View analyst ratings for Krystal Biotech or view top-rated stocks.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Krystal Biotech.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) posted its quarterly earnings results on Monday, May, 9th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.10.
View Krystal Biotech's earnings history.

What price target have analysts set for KRYS?

6 analysts have issued 12 month price targets for Krystal Biotech's stock. Their forecasts range from $93.00 to $110.00. On average, they anticipate Krystal Biotech's share price to reach $101.60 in the next twelve months. This suggests a possible upside of 80.2% from the stock's current price.
View analysts' price targets for Krystal Biotech or view top-rated stocks among Wall Street analysts.

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:

• Mr. Krish S. Krishnan M.B.A., M.S., Founder, Chairman, Pres & CEO (Age 57, Pay $1.01M)
• Ms. Suma M. Krishnan, Founder, COO, Pres of R&D and Director (Age 57, Pay $708.56k) (LinkedIn Profile)
• Ms. Kathryn A. Romano, Exec. VP & Chief Accounting Officer (Age 40, Pay $452.43k)
• Dr. Jing L. Marantz M.B.A., M.D., Ph.D., Exec. VP & Chief Bus. Officer (Age 57, Pay $46.7k)
• Dr. Andreas C. Orth, Exec. VP & Chief Commercial Officer (Age 52, Pay $549.17k)
• Ms. Gloria Lin, Accounting Mang.
• Ms. Meg Dodge, VP of Investor Relations & Corp. Communications
• Mr. David Glynn, Gen. Counsel, Commercial & Compliance
• Mr. John Karakkal, VP of North American Sales & Marketing
• Ms. Katherine Tuminello, HR & Office Mang.

Who are some of Krystal Biotech's key competitors?

Some companies that are related to Krystal Biotech include Halozyme Therapeutics (HALO), Ginkgo Bioworks (DNA), Novavax (NVAX), CRISPR Therapeutics (CRSP), Ablynx (ABLYF), Abcam (ABCM), Vir Biotechnology (VIR), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Fate Therapeutics (FATE), Iovance Biotherapeutics (IOVA), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), Relay Therapeutics (RLAY) and BioCryst Pharmaceuticals (BCRX).
View all of KRYS's competitors.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.68%), Lord Abbett & CO. LLC (4.60%), Vanguard Group Inc. (4.10%), First Light Asset Management LLC (2.80%), Artal Group S.A. (1.98%) and Dimensional Fund Advisors LP (1.02%).
View institutional ownership trends for Krystal Biotech.

Which major investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Verition Fund Management LLC, Cutler Group LP, Simplex Trading LLC, Citigroup Inc., Jacob Asset Management of New York LLC, Kynam Capital Management LP, and SG Americas Securities LLC.
View insider buying and selling activity for Krystal Biotech or view top insider-selling stocks.

Which major investors are buying Krystal Biotech stock?

KRYS stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, BlackRock Inc., Jennison Associates LLC, JPMorgan Chase & Co., C WorldWide Group Holding A S, First Light Asset Management LLC, Nicholas Investment Partners LP, and Vanguard Group Inc..
View insider buying and selling activity for Krystal Biotech or or view top insider-buying stocks.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $56.38.

How much money does Krystal Biotech make?

Krystal Biotech has a market capitalization of $1.45 billion. The company earns $-69.57 million in net income (profit) each year or ($4.37) on an earnings per share basis.

How many employees does Krystal Biotech have?

Krystal Biotech employs 119 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at (412) 586-5830 or via email at [email protected].